EHMT1 and cancer: Unrelated to EHMT1/2, CHKA is a key enzyme in phosphatidylcholine metabolism and has been proposed as an anti‐cancer target, with one inhibitor previously evaluated in clinical trials.[8] We confirm CHKA cellular target engagement by UNC0737 and UNC0638 resulting in perturbation of phosphocholine metabolism.